Neuroprotective potential of combination of resveratrol and 4-amino 1,8 naphthalimide in experimental diabetic neuropathy: focus on functional, sensorimotor and biochemical changes.
The present study investigated whether combination of resveratrol and 4-amino 1,8 naphthalimide (4-ANI) is effective in the development of diabetic neuropathy (DN). After 6 weeks of diabetes induction, rats were treated for 2 weeks with resveratrol and 4-amino 1,8 naphthalimide (4-ANI) either alone or in combination. Experimental end points included functional, behavioural and biochemical parameters along with PAR immunohistochemistry and were performed at the end of treatment. Combination of resveratrol (10 mg/kg) and 4-ANI (3 mg/kg) attenuated conduction and nerve blood flow deficits and resulted in amelioration of diabetic neuropathic pain. Significant reversal of biochemical alterations (peroxynitrite, MDA and NAD levels) were also observed, as well as PAR accumulation in the sciatic nerve. This study suggests the beneficial effect of combining resveratrol and 4-ANI in experimental diabetic neuropathy.
Sharma
Shyam S
SS
Molecular Neuropharmacology Laboratory, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Sector-67, S.A.S. Nagar, Mohali, Punjab-160062, India. sssharma@niper.ac.in
Kumar
Ashutosh
A
Arora
Manish
M
Kaundal
Ravinder K
RK
D015057:1-Naphthylamine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009243:NAD / Q000378:metabolism; D053644:Naphthalimides / Q000008:administration & dosage*; D009431:Neural Conduction / Q000187:drug effects; D009437:Neuralgia / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D018384:Oxidative Stress / Q000187:drug effects; D010147:Pain Measurement; D030421:Peroxynitrous Acid / Q000378:metabolism; D011064:Poly Adenosine Diphosphate Ribose / Q000378:metabolism; D015363:Quinolones / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D012584:Sciatic Nerve / Q000187:drug effects / Q000503:physiopathology; D013267:Stilbenes / Q000008:administration & dosage*
D000975:Antioxidants; D053644:Naphthalimides; D018696:Neuroprotective Agents; D015363:Quinolones; D013267:Stilbenes; D009243:NAD; D030421:Peroxynitrous Acid; C086538:4-amino-1,8-naphthalimide; D011064:Poly Adenosine Diphosphate Ribose; D008315:Malondialdehyde; D015057:1-Naphthylamine; D000077185:Resveratrol